

ABSTRACT SUBMISSION AUTHOR GUIDELINES

FOR BIOTECH SHOWCASE SESSION

A. GENERALITIES

This online abstract submission will close on **October 5, 2026**. No late abstracts will be accepted. Presenting authors will be notified of the Scientific Committee's decision regarding acceptance of their abstracts. Presenting authors must be registered to ICFSR27 by **December 15, 2026** or their abstract will be discarded from the program.

Only abstracts submitted via the online system will be taken into account. Please do not send abstracts by email, as they will not be considered.

Please note that abstracts submitted in this category will not be considered for any other categories. **Biotech Showcase is only available to in-person presenters.**

B. STEP-BY-STEP ONLINE SUBMISSION GUIDELINES

Step 1: Please indicate the type of presentation you are submitting for.

Attention: you must select oral communication.

Step 2: In the scroll-down menu for topics, make sure you select the topic:

VII. BIOTECH SHOWCASE SESSIONS

Step 3: Enter the abstract title. Please do not capitalize the letters.

Step 4: Enter the name and affiliation of the presenting author (the person presenting the abstract at the conference, not necessarily the main author).

- Enter names and affiliations of co-authors as needed. A maximum of 15 co-authors is allowed.

Step 5: Enter all the emails from the presenting author and co-authors.

Step 6: In the dedicated box, please enter the key takeaway message (maximum 35 words) for your abstract.

Step 7: Enter all the different elements of your abstract in the dedicated abstract box, following the structure below.

Company Therapeutic Area

One line. Indicate the disease area or pathology addressed, and its relevance to frailty, sarcopenia, and healthy longevity (e.g., co-pathology, biomarker, drug target, digital health, etc.).

Company & Pipeline Description (200 words maximum)

Briefly describe the company, its mission, and the investment highlights, including pipeline and key technology platforms. Focus on what the company does and where it stands in development, rather than abstract-style background/methods/results.

Describe the Innovation, Product, or Device to Be Presented (400 words maximum)

Describe the specific and differentiating innovation, product, or device featured in this presentation. Explain what it does, what stage of development or validation it has reached, and why it is clinically or scientifically relevant to frailty, sarcopenia, or healthy aging. Supporting publications should be listed here, in standard citation format with PMID/DOI where available.

Highlight the Underlying Scientific Data to Be Presented (400 words maximum)

Summarize the key data supporting the innovation described above. Specify the study design or model used (e.g., preclinical, Phase 1/2/3, real-world cohort), the primary endpoints or outcome measures, and the headline results, including relevant statistics where available (effect size, p-values, sensitivity/specificity). Indicate the sample size and population studied. If data are preliminary or unpublished, state this explicitly. Focus on results most relevant to differentiating the product within the frailty/healthy aging field, rather than full methodological detail.

Name, Title, and Email of Presenter

Full name, credentials, title/role at the company, and email address.

C. AUTHOR INSTRUCTIONS

- **Abstract selection:** Abstracts are selected on a peer-review basis by the ICFSR Scientific Committee.
- **Abstract publication:** Abstracts accepted for presentation in the Biotech Showcase will not be featured in the Journal of Frailty and Aging.